Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

52.61USD
25 Sep 2017
Change (% chg)

$0.10 (+0.19%)
Prev Close
$52.51
Open
$52.46
Day's High
$52.78
Day's Low
$52.31
Volume
2,727,350
Avg. Vol
1,723,083
52-wk High
$52.78
52-wk Low
$37.38

Latest Key Developments (Source: Significant Developments)

Abbott secures FDA approval for MRI-compatibility for the co's Ellipse ICD
Friday, 22 Sep 2017 08:00am EDT 

Sept 22 (Reuters) - Abbott Laboratories :Abbott secures FDA approval for MRI-compatibility for the company's Ellipse ICD.  Full Article

Abbott announces extension of cash tender offer
Monday, 18 Sep 2017 08:01am EDT 

Sept 18 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - ‍ offer will now expire at 11:59 p.m., New York City time, on Friday, Sept. 29, 2017​.  Full Article

Quidel announces revised agreement for pending acquisition of Alere’s business
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Quidel Corp :Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers.Quidel - ‍ previously announced transaction to purchase Triage Meterpro cardiovascular and toxicology assets from alere remains substantially unchanged​.Quidel-‍revised agreement provides co direct commercial responsibility after purchase for all sales globally of Alere's BNP assay unit run on Beckman Analyzers​.Quidel Corp - ‍ transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - ‍total cash consideration for Alere's Triage MeterPro assets and beckman coulter bnp sales​ will now be up to $680 million.Quidel Corp - ‍ believe co is on track to close acquisition of Triage and BNP businesses within 30 days of Abbott's close of Alere acquisition​.Quidel- deal consideration of $680 million made of $400 million purchase price for triage business, $40 million in contingent consideration for eea bnp business.Quidel- deal consideration of $680 million also comprised of $240 million in deferred consideration for rest-of-world BNP business​.  Full Article

Abbott sets quarterly dividend of $0.265 per share
Thursday, 14 Sep 2017 12:30pm EDT 

Sept 14 (Reuters) - Abbott ::Sets quarterly dividend of $0.265 per share.  Full Article

Abbott Laboratories says ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system
Wednesday, 13 Sep 2017 07:01am EDT 

Sept 13 (Reuters) - Abbott Laboratories :Abbott Laboratories - ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system for people with diabetes using insulin​.Abbott Laboratories - ‍ from Nov. 1, 2017 FreeStyle Libre flash glucose monitoring technology will be available for reimbursement via NHS ​.  Full Article

Abbott initiates study of AMPLATZER device to correct congenital heart defect in newborns
Wednesday, 30 Aug 2017 11:56am EDT 

Aug 30 (Reuters) - Abbott Laboratories :Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns.‍Study of AMPLATZER device​ will enroll approximately 50 patients at up to 10 centers across United States.  Full Article

U.S. FDA says has approved St. Jude medical’s firmware update ‍​
Tuesday, 29 Aug 2017 01:03pm EDT 

Aug 29 (Reuters) - U.S. Food and Drug Administration::U.S. FDA says has approved St. Jude medical’s firmware update ‍​.  Full Article

Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​
Wednesday, 16 Aug 2017 06:18am EDT 

Aug 16 (Reuters) - Enzo Biochem Inc ::Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​.U.S. Court's order ‍denies summary judgment that U.S. Patent no. 8,097,405 is invalid for lack of written description.‍U.S. Court's order also granted summary judgment that U.S. Patent no. 8,097,405​ is invalid for lack of enablement.‍Enzo "disagrees" with court's decision, and is exploring options for review of decision​.  Full Article

Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc
Monday, 14 Aug 2017 08:00am EDT 

Aug 14 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc.Abbott Laboratories - ‍offer was previously scheduled to expire on Aug. 11, 2017 and will now expire, on Thursday, Aug. 31, 2017​.  Full Article

Abbott Laboratories says entered into term loan agreement with lenders
Monday, 31 Jul 2017 05:42pm EDT 

July 31 (Reuters) - Abbott Laboratories ::Abbott Laboratories - on july 31, co, entered into term loan agreement with lenders and Bank Of America, N.A., as administrative agent.Abbott Laboratories - loans will be made in a single borrowing and mature and be payable in full 5 years after date of such borrowing.Abbott Laboratories says term loan agreement provides co ability to borrow up to $2.8 billion on unsecured basis to finance Alere acquisition - sec filing.  Full Article

BRIEF-Abbott secures FDA approval for MRI-compatibility for the co's Ellipse ICD

* Abbott secures FDA approval for MRI-compatibility for the company's Ellipse ICD Source text for Eikon: Further company coverage: